See more : Synopex Inc. (025320.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of VistaGen Therapeutics, Inc. (VTGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VistaGen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Investeringsforeningen Pfa Invest – Balance C Akkumulerende (PFIBCA.CO) Income Statement Analysis – Financial Results
- Brain Scientific Inc. (BRSF) Income Statement Analysis – Financial Results
- Step One Clothing Limited (STP.AX) Income Statement Analysis – Financial Results
- Futaba Industrial Co., Ltd. (7241.T) Income Statement Analysis – Financial Results
- Hokuriku Electrical Construction Co.,Ltd. (1930.T) Income Statement Analysis – Financial Results
VistaGen Therapeutics, Inc. (VTGN)
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 103.10K | 91.20K | 80.70K | 0.00 | 53.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 20.02M | 44.38M | 35.41M | 11.93M | 13.37M | 17.10M | 7.76M | 5.20M | 3.93M | 2.43M | 2.48M | 3.43M | 5.39M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.06M | 14.66M | 10.45M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.39K | 21.54K | 16.35K | 4.78K |
| Selling & Marketing | 0.00 | 1.90M | 2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.06M | 14.66M | 13.25M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.52K | 21.54K | 16.35K | 4.78K |
| Other Expenses | 0.00 | 0.00 | 232.00K | -400.00 | -827.00K | -48.70K | -428.00K | 426.80K | -2.30K | -233.00K | 0.00 | 0.00 | 641.00K | 428.00 | 428.00 | 36.00 | 0.00 |
| Operating Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Cost & Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Interest Income | 0.00 | 49.00K | 20.00K | 15.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 10.00K | 30.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 23.00K | 0.00 | 13.00K | 15.00K | 8.00K | 8.90K | 5.00K | 777.00K | 4.62M | 1.56M | 1.00M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 568.00K | 532.00K | 711.10K | 477.60K | 103.10K | 91.20K | 80.70K | 54.90K | 53.50K | 59.10K | 54.60K | 33.80K | 45.60K | 428.00 | 428.00 | 36.00 | 0.00 |
| EBITDA | -32.45M | -58.74M | -47.05M | -17.44M | -20.65M | -24.47M | -14.25M | -9.77M | -17.80M | -6.72M | -4.97M | -11.85M | -10.27M | -6.32M | -21.54K | -16.35K | -4.78K |
| EBITDA Ratio | -3,050.09% | 25,816.45% | -4,221.83% | -1,633.87% | 0.00% | 0.00% | 0.00% | -815.46% | 0.00% | 0.00% | 0.00% | -3,340.62% | -670.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -33.02M | -59.27M | -47.78M | -17.93M | -20.80M | -24.56M | -14.20M | -10.25M | -17.85M | -6.78M | -5.03M | -6.79M | -9.04M | -8.95K | -21.97K | -16.39K | -4.78K |
| Operating Income Ratio | -3,103.48% | 26,040.74% | -4,308.68% | -1,646.06% | 0.00% | 0.00% | 0.00% | -819.88% | 0.00% | 0.00% | 0.00% | -3,389.77% | -673.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.66M | 26.00K | 19.90K | 2.20K | 30.10K | -30.70K | -143.90K | -4.60K | -29.37M | -7.11M | 2.06M | -6.09M | -3.16M | -9.47M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -29.36M | -59.24M | -47.76M | -17.93M | -20.77M | -24.59M | -14.34M | -10.25M | -47.22M | -13.88M | -2.97M | -12.88M | -12.21M | -8.95K | -21.97K | -16.39K | -4.78K |
| Income Before Tax Ratio | -2,759.21% | 26,063.26% | -4,306.88% | -1,645.86% | 0.00% | 0.00% | 0.00% | -820.25% | 0.00% | 0.00% | 0.00% | -6,428.64% | -909.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.00K | 6.00K | 3.40K | 2.60K | 2.60K | 2.60K | 2.40K | 2.40K | 2.30K | 2.40K | 2.70K | 3.70K | 1.60K | 30.00 | 30.00 | 30.00 | -30.00 |
| Net Income | -29.36M | -59.25M | -47.76M | -17.93M | -20.77M | -24.59M | -14.35M | -10.26M | -47.22M | -13.89M | -2.97M | -12.89M | -12.21M | -8.98K | -22.00K | -16.42K | -4.75K |
| Net Income Ratio | -2,759.59% | 26,065.86% | -4,307.19% | -1,646.09% | 0.00% | 0.00% | 0.00% | -820.44% | 0.00% | 0.00% | 0.00% | -6,430.49% | -909.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.28 | -318.27 | -74.47 | -426.99 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| EPS Diluted | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.27 | -315.87 | -81.00 | -426.98 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| Weighted Avg Shares Out | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.63K | 39.85K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
| Weighted Avg Shares Out (Dil) | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.96K | 36.64K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the...
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer,...
Vistagen Announces Stockholder-Approved Reverse Stock Split
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse...
Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that positive safety and exploratory...
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that safety and exploratory efficacy...
Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it has been recognized by Mental...
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it has been recognized...
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety...
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety...
Vistagen Receives New European Patent for AV-101
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has...
Source: https://incomestatements.info
Category: Stock Reports